mlck

MLCK inhibitor peptide 18 acetate is a selective competitive inhibitor of myosin light chain kinase (IC50 = 50 nM). Displays 4000-fold selectivity over CaM kinase II and does not inhibit PKA. Cell permeable.

SK-MLCK M13 is a biologically active peptide representing the calmodulin (CaM)-binding domain of CaM target proteins, where CaM is a ubiquitous Ca2+ binding protein.

Selective competitive inhibitor of myosin light chain kinase (IC50 = 50 nM). Displays 4000-fold selectivity over CaM kinase II and does not inhibit PKA. Cell permeable.

Myosin light chain kinase fragment 11-19 amide (MLCK(11-19) amide) serves both as a substrate-specific peptide inhibitor of MLCK and as an inhibitor of hypotonicity-induced Ca2+ entry. This compound has applications in the research of human cervical cancer [1] [2].

Thymosin β4 (cattle), a Ca2+-independent MLCK activator, demonstrates high affinity [1].

Calmodulin Binding Peptide 1, a potent CaM-binding peptide with picomolar (pM) affinity, originates from smooth muscle myosin light-chain kinase (MLCK peptide). It effectively blocks inositol trisphosphate (IP3)-induced calcium (Ca2+) release [1].

Thymosin β4 (cattle) TFA is a high-affinity activator of MLCK that operates independently of Ca2+ [1].